Shire/TKT: The Price of Diversification
Shire's proposed $1.6 billion cash takeover of TKT answers investors' call for some deal-making action and pipeline diversification. But critics say Shire has paid over the odds for some risky programs in unfamiliar territory--rather like it did with BioChem.
You may also be interested in...
The Massachusetts start-up has plans to create five new companies that will focus on rare disease work through an innovative business model that will de-risk the assets before spinning them out into separate biotech companies.
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.
Jeff Jonas takes over Shire’s newly formed Regenerative Medicine business with plans for rapid growth, replacing Advanced BioHealing’s Kevin Rakin in the role.